ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+17.74%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$163M
AUM Growth
+$163M
(-28%)
Cap. Flow
-$54.6M
Cap. Flow
% of AUM
-33.61%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
54
New
8
Increased
9
Reduced
9
Closed
20
Top Buys
| 1 |
Terns Pharmaceuticals
TERN
|
$7.63M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.36M |
| 3 |
Mersana Therapeutics
MRSN
|
$5.57M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$5.09M |
| 5 |
Keros Therapeutics
KROS
|
$3.84M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$17.4M |
| 2 |
Relmada Therapeutics
RLMD
|
$13.5M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$9.84M |
| 4 |
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
|
$8.45M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$7.32M |
Sector Composition
| 1 | Healthcare | 99.99% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
WHWK
1
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $19.6M | 12.08% | 1,849,402 | – | – |
|
2
Viridian Therapeutics
VRDN
$1.5B
| $11.6M | 7.13% | 396,500 +33,765 | +9% | +$986K |
|
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $11.2M | 6.92% | 217,500 -336,500 | -61% | -$17.4M |
|
|
4
Terns Pharmaceuticals
TERN
$609M
| $11.2M | 6.89% | 1,100,000 +749,298 | +214% | +$7.63M |
|
5
United Therapeutics
UTHR
$13.8B
| $9.18M | 5.65% | 33,000 +5,500 | +20% | +$1.53M |
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $8.75M | 5.38% | 67,500 +26,000 | +63% | +$3.37M |
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.26M | 5.08% | 324,614 | – | – |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.72M | 4.75% | 360,500 -203,107 | -36% | -$4.35M |
|
9
Ventyx Biosciences
VTYX
$171M
| $7.56M | 4.65% | 290,500 +110,500 | +61% | +$2.87M |
|
10
Vaxcyte
PCVX
$4B
| $6.93M | 4.26% | 144,500 +59,500 | +70% | +$2.85M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $6.36M | 3.92% | +1,015,000 | New | +$6.36M |
|
12
Kura Oncology
KURA
$686M
| $6.22M | 3.83% | 501,500 -35,000 | -7% | -$434K |
|
|
13
Mersana Therapeutics
MRSN
$36.5M
| $5.57M | 3.43% | +950,000 | New | +$5.57M |
|
|
BLU
14
DELISTED
BELLUS Health Inc.
BLU
| $5.2M | 3.2% | 632,500 -806,000 | -56% | -$6.63M |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $5.13M | 3.15% | 115,000 -152,195 | -57% | -$6.78M |
|
|
16
Rocket Pharmaceuticals
RCKT
$354M
| $5.09M | 3.13% | +260,000 | New | +$5.09M |
|
17
BioAtla
BCAB
$26.7M
| $4.13M | 2.54% | 500,000 -20,000 | -4% | -$165K |
|
18
Aclaris Therapeutics
ACRS
$209M
| $4.02M | 2.47% | 255,000 +94,165 | +59% | +$1.48M |
|
|
19
Keros Therapeutics
KROS
$618M
| $3.84M | 2.36% | +80,000 | New | +$3.84M |
|
20
GH Research
GHRS
$837M
| $2.36M | 1.46% | 243,250 | – | – |
|
21
argenx
ARGX
$43.6B
| $1.93M | 1.19% | +5,100 | New | +$1.93M |
|
22
Arrowhead Research
ARWR
$3.05B
| $1.66M | 1.02% | 41,029 -46,471 | -53% | -$1.88M |
|
23
Fulcrum Therapeutics
FULC
$351M
| $1.35M | 0.83% | 185,000 -35,000 | -16% | -$255K |
|
24
PMV Pharmaceuticals
PMVP
$74.2M
| $1.34M | 0.83% | 154,471 -29 | -0% | -$252 |
|
25
EyePoint Pharmaceuticals
EYPT
$797M
| $1.06M | 0.65% | 303,396 | – | – |
|